Testing a new drug for hard-to-remove giant cell bone tumors
Treatments studied
Part of Cancer clinical trials.
This Phase 3 study tests narlumosbart (JMT103) to see if it works and is safe for people with giant cell tumor of bone that cannot be fully removed with surgery. If you qualify, you may be compared against another treatment and monitored closely for side effects and tumor response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent and fully understand the study
- You’re an adult (18+) or a skeletally mature teen (at least 12) and weigh at least 45 kg
- Your giant cell bone tumor is confirmed by pathology and can’t be safely removed by surgery
- Your general health is good enough for daily activity (ECOG score 0 to 2)
- You do not have serious active mouth/jaw problems (like infections or unhealed dental procedures)
- You can’t be on certain cancer treatments or medicines right now (like radiation/chemo/other anti-cancer therapy or bisphosphonates)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding zoledronic acid (a bone-strengthening medicine) into bone cement at the surgical site can help prevent giant cell bone tumor from coming back after surgeons scrape it out from inside the bone. It is for people whose tumor can be treated with a specific “scrape-and-reconstruct” surgery and who have not had related medicines before.
This study looks at whether taking a bone-strengthening medicine called a bisphosphonate after surgery can lower the chance that a giant cell tumor in a leg or arm comes back. It may help prevent recurrence after removing the tumor from the bone.
This trial tests a new drug called Narlumosbartmab added to standard chemotherapy for certain types of bone cancer that have eaten away at the bone and contain large, abnormal cells. It is for people who have not yet started standard treatment and whose tumors can be removed with surgery.
This trial tests an experimental drug for people with advanced solid tumors, including small cell lung cancer, that have stopped responding to standard treatments. The goal is to find out if the drug is safe and effective.
This trial is testing a new drug called narlumosbart (a type of targeted biologic medicine) compared to denosumab (a standard bone-strengthening treatment) for people with multiple myeloma that has caused bone damage. The goal is to see which drug better protects bones and reduces complications.
This trial tests adding a new drug (narlumosbart) and targeted radiation to standard chemotherapy and immunotherapy for people with advanced non-small cell lung cancer that has spread to the bones. The goal is to see if this combination works better than standard treatment alone.
Hear when a new Giant Cell Tumor of Bone trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.